GLP-1 Agonists for PCOS: Weight, Insulin, Fertility

Peptide Hormone Dysregulation in PCOS

56% prediabetes remission

In women with PCOS, exenatide achieved a 56% prediabetes remission rate versus 32% with metformin alone, alongside greater improvements in insulin resistance and postprandial glucose.

Al-Qudah et al., J Obstetrics and Gynaecology Research, 2025

Al-Qudah et al., J Obstetrics and Gynaecology Research, 2025

View as image

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women of reproductive age, affecting 8-13% of the population depending on diagnostic criteria. The condition involves a self-reinforcing cycle: insulin resistance drives excess androgen production from the ovaries, which disrupts ovulation, promotes weight gain, and worsens insulin resistance further. GLP-1 receptor agonists intervene at multiple points in this cycle simultaneously, producing effects on weight, insulin sensitivity, androgen levels, and potentially ovarian function that go beyond what older treatments achieve. For the broader picture of how peptide hormones become dysregulated in PCOS, see our pillar article on peptide hormone dysregulation in PCOS.

Why PCOS and GLP-1 agonists are a logical match

PCOS sits at the intersection of metabolic and reproductive dysfunction. Approximately 50-70% of women with PCOS have insulin resistance, and 40-80% have overweight or obesity. Insulin resistance in PCOS is not merely a metabolic inconvenience; it is a driver of the disease itself. Hyperinsulinemia stimulates ovarian theca cells to produce excess androgens (testosterone, androstenedione), which suppress follicular maturation, cause anovulation, and produce the clinical features of PCOS: irregular periods, acne, hirsutism, and infertility.

Traditional treatment targets one aspect at a time: metformin for insulin resistance, oral contraceptives for androgen suppression, clomiphene for ovulation induction. GLP-1 receptor agonists are distinct because they simultaneously address weight loss, insulin resistance, and (through mechanisms still being elucidated) potentially ovarian function itself.

Roberts et al. (2026) reviewed the rationale for GLP-1RA use in female reproductive health, concluding that the combination of weight loss, insulin sensitization, and reduced systemic inflammation makes GLP-1RAs theoretically well-suited for PCOS, though the evidence base was still maturing compared to established indications.^[1]

The meta-analysis evidence: what pooled data shows

The Forslund systematic review (2026)

Forslund et al. (2026) published the most comprehensive systematic review and meta-analysis of GLP-1RA treatment in PCOS to date in the European Journal of Endocrinology. Drawing from the Cochrane Library, EMBASE, and PubMed, they pooled data on weight-related, metabolic, and reproductive outcomes.^[2]

Key findings from the meta-analysis:

• Significant reductions in body weight, BMI, and waist circumference compared to placebo or metformin alone
• Significant improvements in fasting insulin, HOMA-IR (insulin resistance index), and triglycerides
• Significant reduction in total testosterone levels
• Gastrointestinal side effects were the most common adverse events but were generally mild and self-limiting

The testosterone reduction is particularly important. Excess androgens are the proximate cause of many PCOS symptoms, and demonstrating that GLP-1RAs lower testosterone levels in pooled data strengthens the case for their use beyond weight management.

Liraglutide-specific meta-analysis

Lu et al. (2026) conducted a meta-analysis focused specifically on liraglutide in women with PCOS. Published in Diabetes, Obesity and Metabolism, this analysis found liraglutide improved metabolic outcomes (weight, insulin resistance, lipid profiles) and reproductive outcomes (menstrual regularity, free androgen index) compared to metformin or placebo.^[3]

The improvement in menstrual regularity is a clinically meaningful endpoint because regular ovulatory cycles are a prerequisite for natural conception and a marker of restored hormonal balance.

Semaglutide meta-analysis

Chen et al. (2025) published a meta-analysis examining semaglutide's effects on BMI and blood lipids in women with PCOS. Pooled data showed significant reductions in BMI, total cholesterol, and triglycerides compared to controls.^[4]

Individual trials: detailed outcomes

Exenatide versus metformin for insulin resistance

Al-Qudah et al. (2025) conducted a trial comparing exenatide plus metformin versus metformin alone in PCOS women with insulin resistance. After 12 weeks, the combination group achieved a 56% prediabetes remission rate versus 32% with metformin alone. The combination also produced superior improvements in HOMA-IR, postprandial glucose, and HbA1c.^[5]

The prediabetes remission finding is striking because PCOS women have a 5-8 fold increased lifetime risk of type 2 diabetes. An intervention that can reverse prediabetes in this population addresses one of the most serious long-term health consequences of the syndrome.

Semaglutide plus metformin: a 100-patient trial

Chen et al. (2025) published a prospective study of 100 overweight or obese PCOS women randomized to metformin monotherapy or semaglutide plus metformin. The combination group showed greater improvements in body weight, metabolic parameters (fasting glucose, insulin, lipids), reproductive function, and inflammatory markers.^[6]

The inclusion of inflammatory markers is relevant because PCOS is increasingly recognized as a state of chronic low-grade inflammation, which contributes to both metabolic dysfunction and reproductive impairment. Elevated C-reactive protein, interleukin-6, and TNF-alpha are commonly found in PCOS and correlate with disease severity. GLP-1RAs have anti-inflammatory properties independent of weight loss, reducing circulating inflammatory markers through direct effects on immune cells and endothelial function. This suggests a multi-mechanism benefit in PCOS that targets inflammation alongside insulin resistance and adiposity.

Semaglutide plus metformin for fertility

Bolek et al. (2026) studied semaglutide combined with metformin specifically for weight loss and fertility outcomes in PCOS. Published in Clinical Nutrition ESPEN, the study found that the combination produced clinically meaningful weight loss that correlated with improved reproductive outcomes.^[7] Weight reduction in PCOS is not merely cosmetic; even a 5-10% body weight loss can restore ovulatory cycles in many women with the condition.

The ovarian question: direct effects beyond weight loss

Celik et al. (2026) reviewed the evidence for direct GLP-1R-mediated effects on reproductive function, separate from the indirect benefits of weight loss and insulin improvement. Published in Obesity Facts, they noted that GLP-1 receptors are expressed on ovarian granulosa cells, and GLP-1R signaling in these cells may influence follicular development and steroidogenesis.^[8]

Voros et al. (2026) published a systematic review in the International Journal of Molecular Sciences specifically examining GLP-1RA effects on reproductive health, integrating IVF data, ovarian physiology, and fertility outcomes. They found evidence that GLP-1R signaling may directly affect ovarian function: preconception liraglutide combined with metformin was superior to metformin alone in increasing IVF pregnancy rates in obese PCOS patients.^[9]

The direct ovarian effects remain the most scientifically interesting but least established aspect of GLP-1RA use in PCOS. If GLP-1R activation independently improves follicular maturation and reduces ovarian androgen production, it would represent a mechanistically novel approach to PCOS treatment that goes beyond the "lose weight and things improve" paradigm.

How GLP-1RAs compare to metformin in PCOS

Metformin has been the standard insulin-sensitizing treatment for PCOS for over two decades. It modestly reduces insulin resistance, promotes small amounts of weight loss (typically 1-3 kg), and can improve menstrual regularity. The question is whether GLP-1RAs offer meaningful advantages.

The available data consistently shows GLP-1RAs produce greater weight loss than metformin (typically 5-15% body weight versus 1-3%), greater insulin resistance reduction, and greater improvements in lipid profiles. The Al-Qudah trial (2025) showed the combination of exenatide plus metformin was substantially superior to metformin alone for prediabetes remission. Lu et al. (2026) found liraglutide superior to metformin for both metabolic and reproductive outcomes.

However, metformin has practical advantages: it is generic, inexpensive, oral, well-studied in pregnancy outcomes (though still controversial), and has decades of safety data in reproductive-age women. GLP-1RAs are injectable (except oral semaglutide), expensive, not studied for safety during pregnancy, and require washout before conception. The clinical decision involves weighing greater efficacy against greater cost, complexity, and limited pregnancy safety data.

For most PCOS patients, the current evidence supports GLP-1RAs as an addition to metformin rather than a replacement, with discontinuation before planned conception and potential restart postpartum if metabolic management is needed.

Metabolic benefits specific to PCOS

Alawami et al. (2026) documented the metabolic benefits of semaglutide specifically in obese PCOS women in a study published in the Irish Journal of Medical Science. They found improvements in metabolic markers including fasting insulin, HOMA-IR, and lipid profiles, consistent with the larger meta-analyses.^[10]

The metabolic benefits of GLP-1RAs in PCOS extend beyond diabetes prevention:

• Cardiovascular risk reduction: PCOS women have 2-4 fold elevated cardiovascular risk compared to age-matched women without PCOS. Improvements in lipids, inflammation, blood pressure, and insulin resistance directly address modifiable risk factors
• Non-alcoholic fatty liver disease: affects up to 40% of PCOS women and is improved by GLP-1RA-mediated weight loss and direct hepatic effects
• Sleep apnea: more prevalent in PCOS than in BMI-matched controls, and improved by weight reduction
• Mental health: PCOS is associated with higher rates of depression and anxiety, and weight loss and hormonal improvement may have indirect benefits on psychological well-being, though this has not been directly studied in GLP-1RA PCOS trials

Limitations and open questions

The current evidence has clear limitations:

Trial size and duration. Most PCOS-specific GLP-1RA trials enrolled 30-100 participants over 12-24 weeks. Larger, longer trials are needed to confirm durability of reproductive outcomes and assess long-term safety in this population.

Pregnancy safety. GLP-1RAs are not approved for use during pregnancy, and most studies required washout before conception. The optimal timing (how long before conception to stop GLP-1RA treatment) and whether preconception benefits persist after discontinuation are not established.

Head-to-head comparisons. Limited data directly compares semaglutide versus liraglutide versus exenatide in PCOS. Agent-specific effects on reproductive outcomes may differ given their pharmacokinetic profiles.

Selection bias. Most trials enrolled overweight or obese PCOS women. Whether lean PCOS patients (who still have insulin resistance and hyperandrogenism) benefit from GLP-1RAs is unknown.

Mechanism clarity. Whether reproductive improvements are entirely weight-mediated or whether direct ovarian GLP-1R effects contribute independently is unresolved. The answer has implications for which patients benefit most and whether GLP-1RAs offer something metformin does not.

Off-label status. No GLP-1RA is currently FDA-approved specifically for PCOS. All use in PCOS is off-label, though the evidence base is rapidly growing and several clinical trials specifically evaluating GLP-1RAs for PCOS endpoints are underway. The gap between the evidence supporting use and the regulatory status means insurance coverage can be inconsistent, and prescription depends heavily on the treating physician's familiarity with the literature.

Weight regain after discontinuation. Studies of GLP-1RA discontinuation in obesity populations show substantial weight regain within months. For PCOS women who achieved metabolic and reproductive improvements through GLP-1RA-mediated weight loss, the question of whether to continue long-term treatment (with conception washout periods) or whether the improvements persist after discontinuation is clinically urgent. No PCOS-specific discontinuation data exists, and this represents one of the most important unanswered questions for clinical practice.

For how kisspeptin dysregulation interacts with GnRH pulsatility in PCOS, see the sibling article on kisspeptin and PCOS.

The Bottom Line

GLP-1 receptor agonists address multiple aspects of PCOS simultaneously: weight loss, insulin sensitization, androgen reduction, and potentially direct ovarian effects through GLP-1 receptors on granulosa cells. Meta-analyses confirm significant improvements in body weight, BMI, insulin resistance, testosterone levels, and menstrual regularity. Individual trials show exenatide plus metformin achieves 56% prediabetes remission, semaglutide plus metformin improves fertility markers, and preconception liraglutide increases IVF pregnancy rates. The evidence base is growing but consists mostly of small, short-term trials. Whether direct ovarian GLP-1R effects contribute independently of weight loss remains the key mechanistic question.

Frequently Asked Questions

Do GLP-1 drugs help with PCOS?

A 2026 systematic review and meta-analysis found GLP-1 receptor agonists significantly reduced body weight, insulin resistance, triglycerides, and total testosterone in women with PCOS compared to placebo or metformin alone (Forslund et al., 2026). They also improved menstrual regularity and reproductive markers. GLP-1RAs address multiple PCOS drivers simultaneously, which is why they are increasingly studied for this condition.

Can semaglutide improve fertility in PCOS?

Semaglutide combined with metformin improved body weight, metabolic parameters, and reproductive function versus metformin alone in a 100-patient trial (Chen et al., 2025). Bolek et al. (2026) found the combination produced weight loss that correlated with improved fertility outcomes. However, semaglutide is not approved during pregnancy and must be stopped before conception. Most studies show preconception benefits rather than effects during fertility treatment itself.

Is liraglutide better than metformin for PCOS?

A meta-analysis by Lu et al. (2026) found liraglutide improved metabolic outcomes (weight, insulin resistance, lipids) and reproductive outcomes (menstrual regularity, free androgen index) compared to metformin in PCOS women. However, liraglutide is more expensive and not yet specifically approved for PCOS. Most studies examined liraglutide as an addition to metformin rather than a replacement.

How do GLP-1 drugs reduce testosterone in PCOS?

The primary mechanism is indirect: GLP-1RA-mediated weight loss and insulin sensitization reduce hyperinsulinemia, which decreases ovarian theca cell stimulation and androgen production. Additionally, GLP-1 receptors are expressed on ovarian granulosa cells (Celik et al., 2026), raising the possibility of direct modulation of ovarian steroidogenesis, though this mechanism has not been confirmed in human clinical settings.

Can GLP-1 drugs prevent diabetes in PCOS women?

PCOS women have a 5-8 fold increased lifetime risk of type 2 diabetes. Al-Qudah et al. (2025) showed exenatide plus metformin achieved 56% prediabetes remission in PCOS women versus 32% with metformin alone. Combined with the insulin sensitization and weight loss effects documented in meta-analyses, GLP-1RAs appear to be among the most effective pharmacological options for diabetes prevention in this high-risk population.

Do GLP-1 agonists affect ovaries directly?

GLP-1 receptors are expressed on ovarian granulosa cells, and preclinical evidence suggests GLP-1R signaling influences follicular development and steroidogenesis (Celik et al., 2026). Voros et al. (2026) reviewed evidence suggesting direct effects on ovarian physiology. However, separating direct ovarian effects from the indirect benefits of weight loss and insulin improvement in clinical studies remains methodologically challenging.